<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00833794</url>
  </required_header>
  <id_info>
    <org_study_id>MDT3-005</org_study_id>
    <nct_id>NCT00833794</nct_id>
  </id_info>
  <brief_title>A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol HCl Once-a-Day Versus Placebo for the Treatment of Pain Due to Osteoarthritis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Labopharm Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Labopharm Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the analgesic efficacy, safety and clinical benefit
      of Tramadol OAD tablets versus Placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity Score as Measured by the 11-point Pain Intensity-Numerical Rating Scale Score at the End of the Study (Week 12 or Time of Discontinuation)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Pain Intensity Score is an 11-point pain intensity numerical rating scale ranging from 0: no pain to 10: worst possible pain. The mean score at the end of the study (week 12 or time of discontinuation) was calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Score (11-point PINRS) After 6 Weeks of Maintenance Treatment</measure>
    <time_frame>6 weeks</time_frame>
    <description>The Pain Intensity Score is an 11-point pain intensity numerical rating scale ranging from 0: no pain to 10: worst possible pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Score Stratified by Dose, at the End of the Study (Week 12 or Time of Discontinuation)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Pain Intensity Score (an 11-point pain intensity numerical rating scale ranging from 0: no pain to 10: worst possible pain) was stratified by final dose level, at week 12 or time of discontinuation. The final optimum dose level based upon efficacy and tolerability was kept for the entire study. The mean score was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Pain Subscale Score at the End of the Study (Week 12 or Time of Discontinuation)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean WOMAC Pain Subscale score at week 12. The WOMAC scale is a 24-item questionnaire divided in 3 subscales, using a 5-point Likert-scale ranging from no difficulty to extreme difficulty (0-none; 1-slight; 2-moderate; 3-severe; 4-extreme). The WOMAC pain subscale results from the sum of 5 pain questions. The maximum total score is 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Physical Function Subscale Score at the End of the Study (Week 12 or Time of Discontinuation)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean WOMAC Physical Function Subscale score at week 12. The WOMAC scale is a 24-item questionnaire divided in 3 subscales, using a 5-point Likert-scale ranging from no difficulty to extreme difficulty (0-none; 1-slight; 2-moderate; 3-severe; 4-extreme). The WOMAC Physical Function subscale results from the sum of 17 physical function questions and the maximum possible score is 68.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change at the End of the Study (Week 12 or Time of Discontinuation)</measure>
    <time_frame>12 weeks</time_frame>
    <description>This assessment of overall status integrates the effect of the treatment on pain, side effects, and the patient's expectation of pain relief. It is made using a 7-point categorical scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Impression of Change at the End of the Study (Week 12 or Time of Discontinuation)</measure>
    <time_frame>week 12</time_frame>
    <description>This assessment of overall impression of study drug is made using a 7-point categorical scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Response was defined as a decrease of ≥1 point in an 11-point PINRS (11-point pain intensity numerical rating scale ranging from 0: no pain to 10: worst possible pain) from baseline to the last visit. The time to response was estimated using Kaplan-Meier analysis and a 95% CI for the median time was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation Due to Lack of Efficacy</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of patients who discontinued due to lack of efficacy was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation Due to Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of patients who discontinued due to adverse events (AEs). An AE is defined as any untoward medical event that occurs during the course of a clinical investigation in which a patient is administered a pharmaceutical or other therapeutic product. Its occurrence does not necessarily imply a causal relationship with the treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1028</enrollment>
  <condition>Pain</condition>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>1 Tramadol Once A Day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol Once a day</intervention_name>
    <arm_group_label>1 Tramadol Once A Day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Open-Label phase:

          1. Males or females

          2. Must be between the ages of 40-80

          3. Must meet the American College of Rheumatology (ACR) Clinical Classification Criteria
             for Osteoarthritis of the Knee:

               -  Current knee pain

               -  Less than 30 minutes of morning stiffness with or without crepitus on active
                  motion

               -  Confirmation either by arthroscopy or radiologist's report (X-rays showing
                  osteophytes, joint space narrowing or subchondral bone sclerosis {eburnation})
                  within five years prior to entry into the study

          4. Must have a history of exposure to treatment (for pain due to osteoarthritis (OA) of
             the knee) with Non-steroidal anti-inflammatory drugs (NSAIDs), COX II inhibitors or
             tramadol.

          5. Must be taking one of the above medications on a regular basis in the 30 days prior to
             Visit 2 (S0).

          6. Must meet the following criteria for severity of pain at Visit 2 (Day S0):

               -  Have a score of ≥ 4 on the 11-point Numerical Rating Scale (PI-NRS; range: 0-10)

               -  Have a total increase of ≥ 2 points on the 11-point Numerical Rating Scale
                  (range: 0-10) compared to the rating at Visit 1 (Day SX)

          7. Must have a erythrocyte sedimentation rate (ESR) &lt; 40 mm/hr

          8. Must have oral and written language comprehension at a level sufficient to comply with
             the protocol and complete study-related materials

          9. Must have signed and dated an approved written Informed Consent form in French,
             Spanish, English or Romanian, which has also been signed and dated by the Investigator
             (unless otherwise required by the ethics committee), prior to study participation

        Exclusion Criteria for Open-Label phase:

          1. Has known rheumatoid arthritis or any other rheumatic disease

          2. Has secondary arthritis i.e. any of the following: septic arthritis; inflammatory
             joint disease; gout; pseudogout; Paget's disease; target joint fracture; acromegaly;
             fibromyalgia; Wilson's disease; Ochronosis; Haemochromatosis; Osteochondromatosis;
             heritable arthritic disorders; or collagen gene mutations

          3. Has a history of bursitis of the knee (target knee)

          4. Has a history of pain in the ipsilateral hip (target knee)

          5. Has had a meniscal tear in the target knee within the last 12 months

          6. Has had cartilage reconstruction procedure in the target knee

          7. Has had a therapeutic arthroscopy procedure in the target knee within the last 12
             months

          8. Has a Body Mass Index (BMI) greater than 37

          9. Has had a major illness, requiring hospitalisation during the 3 months before
             commencement of the screening period

         10. Is unwilling to stop taking pain medication other than the study medication (for
             arthritis or other types of pain) or is unwilling to stop taking other medications for
             the treatment of OA

         11. Has previously failed treatment with tramadol or discontinued treatment with tramadol
             due to adverse events

         12. Has been taking other opioids (e.g. codeine, oxycodone, hydromorphone, etc.) for
             treatment of OA or other chronic conditions

         13. Has received Corticosteroid Injections in the target knee within the last 3 months or
             Viscous injections in the target knee within the last 6 months

         14. Has had treatment within the last 3 weeks with any of the following medications:
             monoamine oxidase inhibitors; tricyclic antidepressants and other tricyclic compounds
             (e.g. cyclobenzaprine, promethazine); neuroleptics; selective serotonin reuptake
             inhibitors; serotonin-norepinephrine reuptake inhibitors or any other drug that
             reduces seizure threshold

         15. Has had treatment with another investigational agent within the last 30 days

         16. Has a history of seizure disorder other than Infantile Febrile Seizures

         17. Has a previous or current opioid dependency

         18. Has a bowel disease causing malabsorption

         19. Is pregnant, lactating or of childbearing potential and is unwilling to utilise a
             medically approved method of contraception during participation in this clinical trial

         20. Has significant liver disease, defined as active hepatitis or elevated liver enzymes
             &gt;3 times the upper boundary of the normal range

         21. Has significant renal disease (defined as creatinine clearance &lt;30 mL/min

         22. Has a history of current or past substance abuse or dependence, other than nicotine

         23. Has a known and documented allergy to tramadol or any structurally similar drugs (e.g.
             opiates)

         24. Has a known and documented allergy to acetaminophen or any structurally similar drugs

         25. Has any other condition that, in the opinion of the Investigators, would adversely
             affect the patient's ability to complete the study or its measures.

        Inclusion criteria for the double-blinded phase:

          -  Patients must continue to meet the open-label eligibility criteria and

          -  Must have a score of ≥ 4 on the Numerical Rating Scale (NRS) with a total increase of
             ≥ 2 points on the NRS compared to Visit 3(Day R14) and

          -  Must not have taken any of the prohibited medications during the Open-label Phase.

        Exclusion criteria for the double-blinded phase:

          -  Patient Request

          -  Adverse Events that contraindicate further administration of the study medication

          -  Any other situation where in the opinion of the Investigator continued participation
             in the study would not be in the patient's best interest.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=9048</url>
    <description>Approved labelling</description>
  </link>
  <results_reference>
    <citation>Burch F, Fishman R, Messina N, Corser B, Radulescu F, Sarbu A, Craciun-Nicodin MM, Chiriac R, Beaulieu A, Rodrigues J, Beignot-Devalmont P, Duplan A, Robertson S, Fortier L, Bouchard S. A comparison of the analgesic efficacy of Tramadol Contramid OAD versus placebo in patients with pain due to osteoarthritis. J Pain Symptom Manage. 2007 Sep;34(3):328-38. Epub 2007 Jun 21.</citation>
    <PMID>17583466</PMID>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2009</study_first_submitted>
  <study_first_submitted_qc>January 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2009</study_first_posted>
  <results_first_submitted>April 9, 2009</results_first_submitted>
  <results_first_submitted_qc>June 22, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 10, 2009</results_first_posted>
  <last_update_submitted>April 25, 2012</last_update_submitted>
  <last_update_submitted_qc>April 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1 Tramadol Once A Day</title>
        </group>
        <group group_id="P2">
          <title>2 Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Open-label Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1028">Enrolled. Population described in the baseline characteristics is 1023 patients (Open-Label safety).</participants>
                <participants group_id="P2" count="0">No Placebo arm during open-label phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered run-in Period</title>
              <participants_list>
                <participants group_id="P1" count="1027"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Open-Label Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1023"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="646">Randomized in double-blind phase</participants>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="382"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="225"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not complete wash-out period</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>enrolled in error (immediately D/C)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double-blind Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="432">Of the 646 patients who completed the Open-Label phase, 432 were randomized to Tramadol Once A Day</participants>
                <participants group_id="P2" count="214">Of the 646 patients who completed the Open-Label phase, 214 were randomized to Placebo</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="326"/>
                <participants group_id="P2" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 Tramadol Once A Day</title>
        </group>
        <group group_id="B2">
          <title>2 Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="432"/>
            <count group_id="B2" value="214"/>
            <count group_id="B3" value="646"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="252"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.8" spread="9.0"/>
                    <measurement group_id="B2" value="62.3" spread="8.9"/>
                    <measurement group_id="B3" value="62.0" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="275"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity Score as Measured by the 11-point Pain Intensity-Numerical Rating Scale Score at the End of the Study (Week 12 or Time of Discontinuation)</title>
        <description>The Pain Intensity Score is an 11-point pain intensity numerical rating scale ranging from 0: no pain to 10: worst possible pain. The mean score at the end of the study (week 12 or time of discontinuation) was calculated.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis population: all randomized patients who received at least one dose of the randomized study medication regardless of the status of the post-dosing assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Tramadol Once A Day</title>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Score as Measured by the 11-point Pain Intensity-Numerical Rating Scale Score at the End of the Study (Week 12 or Time of Discontinuation)</title>
          <description>The Pain Intensity Score is an 11-point pain intensity numerical rating scale ranging from 0: no pain to 10: worst possible pain. The mean score at the end of the study (week 12 or time of discontinuation) was calculated.</description>
          <population>Full analysis population: all randomized patients who received at least one dose of the randomized study medication regardless of the status of the post-dosing assessment.</population>
          <units>Points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="2.5"/>
                    <measurement group_id="O2" value="4.8" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Score (11-point PINRS) After 6 Weeks of Maintenance Treatment</title>
        <description>The Pain Intensity Score is an 11-point pain intensity numerical rating scale ranging from 0: no pain to 10: worst possible pain</description>
        <time_frame>6 weeks</time_frame>
        <population>Full analysis population: all randomized patients who received at least one dose of the randomized study medication regardless of the status of the post-dosing assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Tramadol Once A Day</title>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Score (11-point PINRS) After 6 Weeks of Maintenance Treatment</title>
          <description>The Pain Intensity Score is an 11-point pain intensity numerical rating scale ranging from 0: no pain to 10: worst possible pain</description>
          <population>Full analysis population: all randomized patients who received at least one dose of the randomized study medication regardless of the status of the post-dosing assessment.</population>
          <units>Points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="2.2"/>
                    <measurement group_id="O2" value="4.5" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Score Stratified by Dose, at the End of the Study (Week 12 or Time of Discontinuation)</title>
        <description>Pain Intensity Score (an 11-point pain intensity numerical rating scale ranging from 0: no pain to 10: worst possible pain) was stratified by final dose level, at week 12 or time of discontinuation. The final optimum dose level based upon efficacy and tolerability was kept for the entire study. The mean score was calculated.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis population: all randomized patients who received at least one dose of the randomized study medication regardless of the status of the post-dosing assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Tramadol Once A Day</title>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
          </group>
          <group group_id="O3">
            <title>Tramadol Once A Day 200 mg</title>
          </group>
          <group group_id="O4">
            <title>Tramadol Once A Day 300 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Score Stratified by Dose, at the End of the Study (Week 12 or Time of Discontinuation)</title>
          <description>Pain Intensity Score (an 11-point pain intensity numerical rating scale ranging from 0: no pain to 10: worst possible pain) was stratified by final dose level, at week 12 or time of discontinuation. The final optimum dose level based upon efficacy and tolerability was kept for the entire study. The mean score was calculated.</description>
          <population>Full analysis population: all randomized patients who received at least one dose of the randomized study medication regardless of the status of the post-dosing assessment.</population>
          <units>Points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="214"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="2.5"/>
                    <measurement group_id="O2" value="4.8" spread="2.4"/>
                    <measurement group_id="O3" value="4.1" spread="2.4"/>
                    <measurement group_id="O4" value="4.4" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC Pain Subscale Score at the End of the Study (Week 12 or Time of Discontinuation)</title>
        <description>Mean WOMAC Pain Subscale score at week 12. The WOMAC scale is a 24-item questionnaire divided in 3 subscales, using a 5-point Likert-scale ranging from no difficulty to extreme difficulty (0-none; 1-slight; 2-moderate; 3-severe; 4-extreme). The WOMAC pain subscale results from the sum of 5 pain questions. The maximum total score is 20.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis population: all randomized patients who received at least one dose of the randomized study medication regardless of the status of the post-dosing assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Tramadol Once A Day</title>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>WOMAC Pain Subscale Score at the End of the Study (Week 12 or Time of Discontinuation)</title>
          <description>Mean WOMAC Pain Subscale score at week 12. The WOMAC scale is a 24-item questionnaire divided in 3 subscales, using a 5-point Likert-scale ranging from no difficulty to extreme difficulty (0-none; 1-slight; 2-moderate; 3-severe; 4-extreme). The WOMAC pain subscale results from the sum of 5 pain questions. The maximum total score is 20.</description>
          <population>Full analysis population: all randomized patients who received at least one dose of the randomized study medication regardless of the status of the post-dosing assessment.</population>
          <units>Points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="4.0"/>
                    <measurement group_id="O2" value="7.5" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC Physical Function Subscale Score at the End of the Study (Week 12 or Time of Discontinuation)</title>
        <description>Mean WOMAC Physical Function Subscale score at week 12. The WOMAC scale is a 24-item questionnaire divided in 3 subscales, using a 5-point Likert-scale ranging from no difficulty to extreme difficulty (0-none; 1-slight; 2-moderate; 3-severe; 4-extreme). The WOMAC Physical Function subscale results from the sum of 17 physical function questions and the maximum possible score is 68.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis population: all randomized patients who received at least one dose of the randomized study medication regardless of the status of the post-dosing assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Tramadol Once A Day</title>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>WOMAC Physical Function Subscale Score at the End of the Study (Week 12 or Time of Discontinuation)</title>
          <description>Mean WOMAC Physical Function Subscale score at week 12. The WOMAC scale is a 24-item questionnaire divided in 3 subscales, using a 5-point Likert-scale ranging from no difficulty to extreme difficulty (0-none; 1-slight; 2-moderate; 3-severe; 4-extreme). The WOMAC Physical Function subscale results from the sum of 17 physical function questions and the maximum possible score is 68.</description>
          <population>Full analysis population: all randomized patients who received at least one dose of the randomized study medication regardless of the status of the post-dosing assessment.</population>
          <units>Points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9" spread="13.4"/>
                    <measurement group_id="O2" value="27.5" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Change at the End of the Study (Week 12 or Time of Discontinuation)</title>
        <description>This assessment of overall status integrates the effect of the treatment on pain, side effects, and the patient's expectation of pain relief. It is made using a 7-point categorical scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse)</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis population: all randomized patients who received at least one dose of the randomized study medication regardless of the status of the post-dosing assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Tramadol Once A Day</title>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Change at the End of the Study (Week 12 or Time of Discontinuation)</title>
          <description>This assessment of overall status integrates the effect of the treatment on pain, side effects, and the patient's expectation of pain relief. It is made using a 7-point categorical scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse)</description>
          <population>Full analysis population: all randomized patients who received at least one dose of the randomized study medication regardless of the status of the post-dosing assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="425"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 = very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 = much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 = minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 = no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 = minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 = much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 = very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Global Impression of Change at the End of the Study (Week 12 or Time of Discontinuation)</title>
        <description>This assessment of overall impression of study drug is made using a 7-point categorical scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse)</description>
        <time_frame>week 12</time_frame>
        <population>Full analysis population: all randomized patients who received at least one dose of the randomized study medication regardless of the status of the post-dosing assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Tramadol Once A Day</title>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Impression of Change at the End of the Study (Week 12 or Time of Discontinuation)</title>
          <description>This assessment of overall impression of study drug is made using a 7-point categorical scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse)</description>
          <population>Full analysis population: all randomized patients who received at least one dose of the randomized study medication regardless of the status of the post-dosing assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 = very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 = much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 = minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 = no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 = minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 = much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 = very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not determined</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response</title>
        <description>Response was defined as a decrease of ≥1 point in an 11-point PINRS (11-point pain intensity numerical rating scale ranging from 0: no pain to 10: worst possible pain) from baseline to the last visit. The time to response was estimated using Kaplan-Meier analysis and a 95% CI for the median time was calculated.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis population: all randomized patients who received at least one dose of the randomized study medication regardless of the status of the post-dosing assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Tramadol Once A Day</title>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Response</title>
          <description>Response was defined as a decrease of ≥1 point in an 11-point PINRS (11-point pain intensity numerical rating scale ranging from 0: no pain to 10: worst possible pain) from baseline to the last visit. The time to response was estimated using Kaplan-Meier analysis and a 95% CI for the median time was calculated.</description>
          <population>Full analysis population: all randomized patients who received at least one dose of the randomized study medication regardless of the status of the post-dosing assessment.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-point response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="14" upper_limit="14"/>
                    <measurement group_id="O2" value="14" lower_limit="14" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-point response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="14" upper_limit="15"/>
                    <measurement group_id="O2" value="15" lower_limit="14" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-point response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="15" upper_limit="35"/>
                    <measurement group_id="O2" value="39" lower_limit="35" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-point response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="14" upper_limit="15"/>
                    <measurement group_id="O2" value="35" lower_limit="35" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-point response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="15" upper_limit="35"/>
                    <measurement group_id="O2" value="77" lower_limit="56" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Discontinuation Due to Lack of Efficacy</title>
        <description>The number of patients who discontinued due to lack of efficacy was reported.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis population: all randomized patients who received at least one dose of the randomized study medication regardless of the status of the post-dosing assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Tramadol Once A Day</title>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Discontinuation Due to Lack of Efficacy</title>
          <description>The number of patients who discontinued due to lack of efficacy was reported.</description>
          <population>Full analysis population: all randomized patients who received at least one dose of the randomized study medication regardless of the status of the post-dosing assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Discontinuation Due to Adverse Events</title>
        <description>The number of patients who discontinued due to adverse events (AEs). An AE is defined as any untoward medical event that occurs during the course of a clinical investigation in which a patient is administered a pharmaceutical or other therapeutic product. Its occurrence does not necessarily imply a causal relationship with the treatment.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis population: all randomized patients who received at least one dose of the randomized study medication regardless of the status of the post-dosing assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Tramadol Once A Day</title>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Discontinuation Due to Adverse Events</title>
          <description>The number of patients who discontinued due to adverse events (AEs). An AE is defined as any untoward medical event that occurs during the course of a clinical investigation in which a patient is administered a pharmaceutical or other therapeutic product. Its occurrence does not necessarily imply a causal relationship with the treatment.</description>
          <population>Full analysis population: all randomized patients who received at least one dose of the randomized study medication regardless of the status of the post-dosing assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1 Tramadol Once A Day</title>
        </group>
        <group group_id="E2">
          <title>2 Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9"/>
                <counts group_id="E2" subjects_affected="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1023"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1023"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1023"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1023"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Popliteal bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1023"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1023"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1023"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1023"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1023"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1023"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1023"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="136"/>
                <counts group_id="E2" subjects_affected="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="86" subjects_affected="66" subjects_at_risk="432"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="73" subjects_affected="61" subjects_at_risk="432"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="28" subjects_affected="26" subjects_at_risk="432"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="40" subjects_affected="29" subjects_at_risk="432"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to submitting results communications, the investigator shall allow Labopharm at least 30 days to review the proposed communication. If the proposed publication/disclosure risks Labopharm’s ability to patent any invention related to the study, the publication or disclosure will be modified or delayed to allow Labopharm to seek patent protection. This statement does not give Labopharm any editorial rights other than to restrict the disclosure of Labopharm’s confidential information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Regulatory Affairs</name_or_title>
      <organization>Labopharm Inc.</organization>
      <phone>1 450 686 1017</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

